

R&D Portfolio June 2022 – 12 treatments delivered

	DISCOVERY			TRANSLATION			DEVELOPMENT		IMPLEMENTATION	
	Screen	Hit-to-lead	Lead optimization	Pre-clinical	Phase I	Phase IIa/ Proof-of-concept	Phase IIb/III	Registration	Treatment access	
Sleeping sickness							Acoziborole + Fexinidazole for <i>T.b. rhodesiense</i> +		Fexinidazole for <i>T.b. gambiense</i> * + Nifurtimox-eflornithine combination therapy (NECT)*	
Leishmaniasis	Screening	Hit-to-lead	S07 series +	DNDI-6174 +	DNDI-6148 +	LXE408 Novartis +	New CL combination New treatments for PKDL	Miltefosine + paromomycin combination (Africa)	SSG&PM (East Africa)*	
		NTD Drug Discovery Booster Hit-to-lead			DNDI-0690 +					New VL treatments (South Asia)*
					GSK899 DDD853651 +					New treatments for HIV/VL*
					CpG-D35 for CL +					New VL treatments (Latin America)*
					GSK245 DDD1305143 +					
Chagas disease	Screening	Hit-to-lead	UW series +	Biomarkers	DNDI-6148 +		New benznidazole regimens		Benznidazole paediatric dosage forms*	
		NTD Drug Discovery Booster Hit-to-lead								
Filaria: River blindness				CC6166 +	Oxfendazole +	Emodepside + Flubentylosin +				
Mycetoma							Fosravuconazole			
Dengue				Pre-clinical profiling						
HIV					5 FC (cryptococcal meningitis)				Super-booster for children with HIV/TB* 4-in-1 (ABC/3TC/LPV/r)* 2-in-1 LPV/r pellets 5 FC, LamB access (crypto meningitis)	
Hepatitis C							Ravidasvir + sofosbuvir +		Ravidasvir* and other DAAs +	
COVID 19/ Pandemic Preparedness	Nucleo- side Booster	Broad-spectrum antivirals Hit-to-lead	TMEM16 series +	Pre-clinical support			ANTICOV			
			Moonshot +							
Malaria »									Fixed-dose combination ASMQ* Fixed-dose combination ASAQ*	

» Implementation transferred to the Medicines for Malaria Venture in 2015

+ NCE (New Chemical Entity)

* Treatments delivered by DNDi with partners

▶ Treatments not delivered by DNDi, but DNDi working on access